Villalobos Anabella
Known title: DirectorCIK: 0001952966
Associated companies
Transaction History
| COYA | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 | View on chart |
| COYA | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
COYA completes enrollment for Phase 2/3 ALS trial
Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.
COYA completes enrollment for Phase 2/3 ALS trial. Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.